非布司他对射血分数保留的心衰患者预后的影响

Effect of Febuxostat on Prognosis of Heart Failure Patients with Ejection Fraction Retention

摘要: 目的：通过病例对照研究评估非布司他对射血分数保留心力衰竭患者的影响。方法：采用病例对照研究方法，连续性收集2014至2017于青岛大学附属医院住院治疗的伴有高尿酸血症的射血分数保留心力衰竭患者，跟踪随访1年的276例，将其分为常规治疗组、非布司他组。常规治疗组采用标准抗心衰治疗；非布司他组在标准抗心衰治疗基础上应用非布司他降尿酸治疗；分别收集随访治疗1年前后血压、血尿酸、心房尿钠肽(BNPB-type natriuretic peptide)水平，利用超声心动图测定的左室射血分数(LVEFleft ventricular ejection fractions)、左房内径(LADleft atrial dimension)、计算左心室重量指数(LVMIleft ventricular mass index)、E/e′比值，记录非布司他组与常规治疗组患者1年心血管事件的发生情况。结果：随访观察12个月后，非布司他组和常规治疗组患者的E/e′、LVMI均呈下降趋势，非布司他组下降更明显，差异有统计学意义(均为P < 0.05)。结论：长期应用非布司他在有效降尿酸的同时可改善射血分数保留心力衰竭患者的预后。

Abstract: Objective: To evaluate the effect of febuxostat on ejection fraction retention in patients with heart failure through a case-control study. Methods: A case-control study was conducted and collected continuously from 2014 to 2017 at Qingdao University. Patients with ejection fraction reserved heart failure with hyperuricemia who were hospitalized in affiliated hospitals were followed up 1. A total of 276 patients were divided into conventional treatment group and non-buxostat group. Standard anti-heart failure therapy was used in the conventional treatment group. On the basis of standard anti-heart failure treatment, febuxostat was used to reduce uric acid. Were collected before and after treatment 1 year follow-up blood pressure, blood uric acid, atrial urinary sodium peptide (BNPB-type natriuretic peptide) levels, measured by echocardiography of left ventricular ejection fraction (LVEFleft ventricular ejection fractions), left atrial diameter (LADleft atrial dimension), calculate the left ventricular mass index (LVMIleft ventricular mass index), E/e′ ratio, record not cloth company he group and routine treatment group patients 1 year the happening of cardiovascular events. Results: After 12 months of follow-up observation, E/e′ and LVMI decreased in both the febuxostat group and the conventional treatment group, while the decline was more obvious in the febuxostat group, with statistically significant differences (all P < 0.05). Conclusion: Long-term application of febuxostat can effectively lower uric acid and improve the prognosis of patients with ejection fraction retention heart failure.